Literature DB >> 19414026

Low dose apomorphine induces context-specific sensitization of hypolocomotion without conditioning: support for a new state dependent retrieval hypothesis of drug conditioning and sensitization.

Priscila Quintanilha Braga1, Flávia Regina Cruz Dias, Robert J Carey, Marinete Pinheiro Carrera.   

Abstract

High doses of apomorphine induce sensitization to locomotor stimulant effects whereas low doses induce locomotor inhibition. We examined whether repeated low dose apomorphine induced sensitization and conditioning to the locomotor inhibitory effect. Three doses of the D1/D2 agonist, apomorphine, were used in a Pavlovian conditioning protocol: 0.05 mg/kg (autoreceptor level), 0.5 and 2.0 mg/kg (post-synaptic level). Rats received 5 daily apomorphine treatments paired or unpaired to an open-field environment (conditioning phase) followed by a saline test (conditioning test) and an apomorphine challenge test (sensitization test). Locomotion was measured for 30 min. During the acquisition phase, the 0.05 mg/kg paired treatment decreased locomotion while the high dose paired treatments increased locomotion. The 0.05 mg/kg paired treatment did not induce conditioning but induced inhibitory locomotor sensitization. The post-synaptic paired treatments produced conditioned and sensitized locomotor stimulation. For the low dose results, we propose an expanded contextual stimulus, which includes interoceptive drug cues. In the sensitization test, the same interoceptive drug cues and test environment cues are present as those during acquisition. In the conditioning test, normative dopaminergic activity is present which generates internal cues that may or may not generalize to the drug-induced cues and, permit or prevent retrieval of conditioning.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19414026     DOI: 10.1016/j.pbb.2009.04.019

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  6 in total

1.  Memory re-consolidation and drug conditioning: an apomorphine conditioned locomotor stimulant response can be enhanced or reversed by a single high versus low apomorphine post-trial treatment.

Authors:  Marinete Pinheiro Carrera; Robert J Carey; Flávia Regina Cruz Dias; Liana Wermelinger de Mattos
Journal:  Psychopharmacology (Berl)       Date:  2011-09-16       Impact factor: 4.530

2.  Residual dopamine receptor desensitization following either high- or low-dose sub-chronic prior exposure to the atypical anti-psychotic drug olanzapine.

Authors:  Flávia Regina Cruz Dias; Liana Wermelinger de Matos; Maria de Fátima Dos Santos Sampaio; Robert J Carey; Marinete Pinheiro Carrera
Journal:  Psychopharmacology (Berl)       Date:  2012-07-24       Impact factor: 4.530

3.  Time-dependent effects of prazosin on the development of methamphetamine conditioned hyperactivity and context-specific sensitization in mice.

Authors:  André O White; Anthony S Rauhut
Journal:  Behav Brain Res       Date:  2014-01-31       Impact factor: 3.332

4.  Apomorphine-induced context-specific behavioural sensitization is prevented by the D1 antagonist SCH-23390 but potentiated and uncoupled from contextual cues by the D2 antagonist sulpiride.

Authors:  Flávia Regina Cruz Dias; Robert J Carey; Marinete Pinheiro Carrera
Journal:  Psychopharmacology (Berl)       Date:  2010-02-23       Impact factor: 4.530

5.  Opposite effects of typical and atypical anti-psychotic drugs on sensitized dopamine receptors: sub-chronic low dose Olanzapine exposure reverses sensitization but a similar regimen of low dose haloperidol potentiates sensitization effects.

Authors:  Flávia Regina Cruz Dias; João Marcos de Mello Bastos; Maria de Fátima Dos Santos Sampaio; Robert J Carey; Marinete Pinheiro Carrera
Journal:  Psychopharmacology (Berl)       Date:  2013-07-12       Impact factor: 4.530

6.  Galphimia glauca and Natural Galphimines Block Schizophrenia-Like Symptoms Induced with Apomorphine and MK-801 in Mice.

Authors:  Mayra Alejandra Santillán-Urquiza; Maribel Herrera-Ruiz; Alejandro Zamilpa; Enrique Jiménez-Ferrer; Rubén Román-Ramos; Elian Yuritzi Alegría-Herrera; Jaime Tortoriello
Journal:  Evid Based Complement Alternat Med       Date:  2019-07-21       Impact factor: 2.629

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.